Zynerba Pharmaceuticals (NASDAQ:ZYNE) is a clinical stage biopharmaceutical company developing its proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery. The lead product candidates a are ZYN002 and ZYN001. ZYN002, is in Phase 2 clinical trial for adult patients with refractory epileptic focal seizures and osteoarthritis, as well as pediatric patients with fragile X syndrome; and ZYN001 is in preclinical stage for the treatment of fibromyalgia and peripheral neuropathic pain. Zynerba has the global ownership of these two proprietary lead product candidates which is being develop to treat diseases with significant unmet medical need and market potential.
Zynerba is expected to announce topline data from the phase 2 clinical trial of its lead product candidate ZYN002, a CBD gel developed using its proprietary synthetic cannabinoid therapeutics formula. The results from the phase 1 trial were promising. Adverse events with ZYN002 in healthy volunteers and epilepsy